Table 2. Overall survival by treatment subgroup (ITT population).
| Treatment subgroup comparison | No. of events | Median time to event (months) | Hazard ratio (97.5% CI) |
|---|---|---|---|
| FOLFOX4/FOLFOX4-placebo/FOLFOX4-bevacizumab | 847 | 19.5 | 0.95 (0.85–1.06) |
| XELOX/XELOX-placebo/XELOX-bevacizumab | 820 | 19.8 | |
| FOLFOX4/FOLFOX4-placebo | 573 | 18.9 | 0.95 (0.83–1.09) |
| XELOX/XELOX-placebo | 546 | 19.0 | |
| FOLFOX4-bevacizumab | 274 | 21.0 | 0.95 (0.78–1.15) |
| XELOX-bevacizumab | 274 | 21.6 | |
| FOLFOX4 | 284 | 17.7 | 0.87 (0.72–1.05) |
| XELOX | 266 | 18.8 |
Abbreviations: ITT=intent-to-treat; CI=confidence interval; FOLFOX4=infused fluorouracil, folinic acid and oxaliplatin; XELOX=capecitabine and oxaliplatin.